TY - JOUR
T1 - Optimal scheduling of the nanoparticle-mediated cancer photo-thermo-radiotherapy
AU - Safari, Arash
AU - Sarikhani, Abolfazl
AU - Shahbazi-Gahrouei, Daryoush
AU - Alamzadeh, Zahra
AU - Beik, Jaber
AU - Dezfuli, Amin Shiralizadeh
AU - Mahabadi, Vahid Pirhajati
AU - Tohfeh, Maryam
AU - Shakeri-Zadeh, Ali
N1 - Funding Information:
This study was funded by Iran University of Medical Sciences & Isfahan University of Medical Sciences .
Funding Information:
This study was funded by Iran University of Medical Sciences & Isfahan University of Medical Sciences.
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/12
Y1 - 2020/12
N2 - Maximal synergistic effect between photothermal therapy and radiotherapy (RT) may be achieved when the interval between these two modalities is optimal. In this study, we tried to determine the optimal schedule of the combined regime of RT and nano-photothermal therapy (NPTT), based on the cell cycle distribution and kinetics of cell death. To this end, alginate-coated iron oxide-gold core-shell nanoparticles (Fe3O4@Au/Alg NPs) were synthesized, characterized, and their photo-radio sensitization potency was evaluated on human nasopharyngeal cancer KB cells. Our results demonstrated that synthesized NPs have a good potential in radiotherapy and near-infrared (NIR) photothermal therapy. However, results from flow cytometry analysis indicated that a major portion of KB cells were accumulated in the most radiosensitive phases of cell cycle (G2/M) 24 h after NPTT. Moreover, the maximal synergistic anticancer efficacy (12.3% cell viability) was observed when RT was applied 24 h following the administration of NPTT (NPs [30 μg/mL, 4 h incubation time] + Laser [808 nm, 1 W/cm2, 5 min] + RT [6 Gy]). It is noteworthy that apoptosis was the dominant cell death pathway in the group of cells treated by combination of NPTT and RT. This highly synergistic anticancer efficacy provides a mechanistic basis for Fe3O4@Au/Alg NPs-mediated photothermal therapy combined with RT. Knowing such a basis is helpful to promote novel nanotechnology cancer treatment strategies.
AB - Maximal synergistic effect between photothermal therapy and radiotherapy (RT) may be achieved when the interval between these two modalities is optimal. In this study, we tried to determine the optimal schedule of the combined regime of RT and nano-photothermal therapy (NPTT), based on the cell cycle distribution and kinetics of cell death. To this end, alginate-coated iron oxide-gold core-shell nanoparticles (Fe3O4@Au/Alg NPs) were synthesized, characterized, and their photo-radio sensitization potency was evaluated on human nasopharyngeal cancer KB cells. Our results demonstrated that synthesized NPs have a good potential in radiotherapy and near-infrared (NIR) photothermal therapy. However, results from flow cytometry analysis indicated that a major portion of KB cells were accumulated in the most radiosensitive phases of cell cycle (G2/M) 24 h after NPTT. Moreover, the maximal synergistic anticancer efficacy (12.3% cell viability) was observed when RT was applied 24 h following the administration of NPTT (NPs [30 μg/mL, 4 h incubation time] + Laser [808 nm, 1 W/cm2, 5 min] + RT [6 Gy]). It is noteworthy that apoptosis was the dominant cell death pathway in the group of cells treated by combination of NPTT and RT. This highly synergistic anticancer efficacy provides a mechanistic basis for Fe3O4@Au/Alg NPs-mediated photothermal therapy combined with RT. Knowing such a basis is helpful to promote novel nanotechnology cancer treatment strategies.
KW - Nanoparticles
KW - Optimal scheduling
KW - Photothermal therapy
KW - Radiation therapy
KW - Synergistic effect
UR - http://www.scopus.com/inward/record.url?scp=85094614395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094614395&partnerID=8YFLogxK
U2 - 10.1016/j.pdpdt.2020.102061
DO - 10.1016/j.pdpdt.2020.102061
M3 - Article
C2 - 33068822
AN - SCOPUS:85094614395
SN - 1572-1000
VL - 32
JO - Photodiagnosis and photodynamic therapy
JF - Photodiagnosis and photodynamic therapy
M1 - 102061
ER -